0

Shopping cart

0 items - $0.00

Set Descending Direction
Page:
  1. 1
  2. 2

Preclinical and Personalized Breast Cancer Research

Dear Reader,

As a scientist involved in life science research, I’d like to let you know about the research project on breast cancer, led by the Brisken Lab in EPFL, Switzerland. The scientific team of GEG Tech is proud to be a part of it, designing advanced vectorization systems required by this promising research.

Please find a short presentation about the research project here.

I would be happy to discuss further, should you be interested in this breast cancer research, and/or more generally on our know-how on advanced vectorization systems.

Kind regards,
Nicolas

Episomal lentiviral vectors confer erythropoietin expression in dividing cells

Lentiviral vectors have evolved over the last decade as powerful and reliable gene transfer tools for dividing and non-dividing cells because they possess a large packaging capacity, weak immunogenesis, and a high flexible of design. However, in some cases, the integrating feature of lentiviral vectors may cause unbalanced gene expression, gene silencing and insertional mutagenesis. The sMARt design of non-integrating lentiviral vectors (NILV) can avoid these problems because they do not integrate into the cell genome.

In the related study, the scientists incorporated a tetramer of a 155-bp module from human β-interferon S/MAR sequences into non-integrating lentiviral vectors. This tetramer sequence can function as an origin of replication and maintain the episomal replication of the NILV in dividing cells. They tested an S/MAR-based NILV to see whether it can maintain a therapeutic gene expression in dividing cells. They observed that S/MAR can retain episomal expression through successive rounds of cell division up to 74 days.

GEG Tech offers a wide range of lentiviral vectors including Lenti-ONE EPI (ie NILV) which induce transient expression in dividing cells and stable expression in non-dividing cells. GEG Tech has observed more than one year of in vivo expression after injection in the retina of mice with Lenti-ONE EPI.

Furthermore, GEG Tech provides several types of Lenti-ONE EPI which have different features of expression to adjusting your project.

To know more about the Article

To know more about Lenti-ONE EPI

To know more about GEG Tech

Over the last years, new genetic engineering technologies have emerged and undoubtedly show up game-changing. Genome engineering is since a long time explored and used because there is a lot at stake here in many fields

Read More

A significant recent advance in genome engineering is the development of the CRISPR/Cas9 system for nuclease based genome editing. However, several cell types are not easily transfected and in vivo delivery of the CRISPR system remains challenging.

Read More

Recombinant proteins of therapeutic use are ideally produced in human cells to ensure appropriate co- and post-translational modifications. 

Read More

If you have been living in a cave (without a connection to Labiotech.eu) during the last few months, you may not know what a CAR-T therapy is. Let me explain!

Read More

Lentiviral vectors are commonly pseudotyped with the heterologous envelope VSV-G due to its broad host tropism and stability conferred.

Read More

Since the last decade, the Lentiviral Vector has emerged as a promising vector for gene delivery.

Read More

Human hematopoietic stem cells (HSCs) are refractory to the lentiviral vector transduction.

Read More

Lentiviral vectors (LVs) are currently considered the gold standard for hematopoietic stem cell (HSC) gene therapy and for immunotherapies with genetically modified T cells. 

Read More
Set Descending Direction
Page:
  1. 1
  2. 2